Trial · NCT07145736
Moxidectin Versus Ivermectin as Mass Drug Administration for the Control of Onchocerciasis and Other Neglected Tropical Diseases
NCT07145736, Phase 4, Recruiting, Kirby Institute
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Moxidectin Versus Ivermectin as Mass Drug Administration for the Control of Onchocerciasis and Other Neglected Tropical Diseases. Trials, record NCT07145736. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07145736
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Moxidectin Versus Ivermectin as Mass Drug Administration for the Control of Onchocerciasis and Other Neglected Tropical Diseases
- NCT number
- NCT07145736
- Status
- Recruiting
- Phases
- Phase 4
- Enrollment
- 52,000 participants, estimated
- Lead sponsor
- Kirby Institute
- Conditions
- Onchocerciasis, Ascaris Lumbricoides Infection, Trichuris Trichiura; Infection, Hookworm Infections, Scabies
- Interventions
- Moxidectin, Ivermectin
- First posted
- 2025-08-28
- Last updated
- 2025-11-21
Source ClinicalTrials.gov
Registered outcomes16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Prevalence of Onchocerca volvulus microfilariae | 36 months after the first intervention | Prevalence of O. volvulus microfilariae at 36 months in skin snips, the marker most likely to show change in the shorter term as demonstrated by the therapeutic trials |
| Secondary | Prevalence of O. volvulus microfilaria/mg skin | 12, 24 and 36 months after the first intervention | |
| Secondary | Microfilariae density (mean, median) | 12, 24 and 36 months after the first intervention | |
| Secondary | Prevalence of nodules | 12, 24 and 36 months after the first intervention | |
| Secondary | Prevalence of onchocerciasis skin disease | 12, 24 and 36 months after the first intervention | |
| Secondary | Proportion of black flies with infective O. volvulus larvae | 12, 24 and 36 months after the first intervention | Infection assessed based on all 3 are markers recommended by WHO to define population-level elimination |
| Secondary | Prevalence of anti-Ov-16 | 12, 24 and 36 months after the first intervention | |
| Secondary | Prevalence of Ascaris lumbricoides | 12, 24 and 36 months after the first intervention | Measured through qPCR |
| Secondary | Intensity of Ascaris lumbricoides infection | 12, 24 and 36 months after the first intervention | Measured through qPCR |
| Secondary | Prevalence of Trichuris trichiura | 12, 24 and 36 months after the first intervention | Measured through qPCR |
1 to 10 of 16Source ClinicalTrials.gov
See all 16 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07145736
GET https://conductscience.org/api/trials/v1/NCT07145736/registered